Q2 FY2026 EarningsQ2 FY26 results beat consensus expectations on the bottom line, with a GAAP EPS of -$0.80 compared to the -$1.36 mean estimate. Net loss of $19.0M was narrower than the $19.9M consensus despite a significant YoY increase in R&D spending to $12.7M. The company remains on track to complete enrollment for the Phase 3 ELAINE-3 trial in 4Q 2026, with topline data expected in 2H 2027.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: LeonaBio(LONA) the EBIT is -19.45 M (-166.8%), Beat estimate;the EPS is -0.8 (+55.56%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITExceed expectations
-0.02B166.81%
-0.02B183.45%
+0.00B16.64%
EPSExceed expectations
-0.855.56%
-1.356724.63%
+0.556730.93%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf